[{"address1": "14/15 Conduit St", "address2": "Floor 4", "city": "London", "zip": "W1S 2XJ", "country": "United Kingdom", "phone": "44 20 7495 2379", "website": "https://okyopharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gary S. Jacob Ph.D.", "age": 76, "title": "CEO & Executive Director", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 588000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael Paul Beck", "age": 66, "title": "Founder", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Keeren  Shah", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rajkumar  Patil Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 1.1, "open": 1.11, "dayLow": 1.01, "dayHigh": 1.11, "regularMarketPreviousClose": 1.1, "regularMarketOpen": 1.11, "regularMarketDayLow": 1.01, "regularMarketDayHigh": 1.11, "beta": -3.363, "volume": 27539, "regularMarketVolume": 27539, "averageVolume": 191230, "averageVolume10days": 907700, "averageDailyVolume10Day": 907700, "bid": 0.9884, "ask": 1.1, "bidSize": 100, "askSize": 100, "marketCap": 35528112, "fiftyTwoWeekLow": 0.808, "fiftyTwoWeekHigh": 2.95, "fiftyDayAverage": 1.20034, "twoHundredDayAverage": 1.445025, "currency": "USD", "enterpriseValue": 35389676, "floatShares": 24494786, "sharesOutstanding": 33836300, "sharesShort": 65931, "sharesShortPriorMonth": 48288, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0019, "heldPercentInsiders": 0.27608, "heldPercentInstitutions": 0.029879998, "shortRatio": 0.78, "shortPercentOfFloat": 0.0027, "bookValue": -0.176, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1680220800, "netIncomeToCommon": -16825460, "trailingEps": -0.57, "enterpriseToEbitda": -2.248, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "OKYO", "underlyingSymbol": "OKYO", "shortName": "OKYO Pharma Limited", "longName": "OKYO Pharma Limited", "firstTradeDateEpochUtc": 1652794200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "96881aa4-5354-3ce6-aa77-ba44f40f7011", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.05, "recommendationKey": "none", "totalCash": 4045381, "totalCashPerShare": 0.12, "ebitda": -15745866, "totalDebt": 2215111, "quickRatio": 0.19, "currentRatio": 0.207, "returnOnAssets": -2.9187, "freeCashflow": -12264394, "operatingCashflow": -9490537, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]